Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data - Scorecard - MDSpire

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • By

  • Igor Snast

  • Yuliya Valdman-Grinshpoun

  • Naji Bathish

  • Hagit Matz

  • Yuri Shclar

  • Sari Murad

  • Tali Czarnowicki

  • Eran Shavit

  • Liuqing Yang

  • Sandra Goss

  • Inbal Piller Maor

  • Assaf Halperin

  • Shiran Naftalberg Blonder

  • Raanan Cohen

  • Alex Bleterman

  • Moran Barak

  • Lev Pavlovsky

  • March 31, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

At a Glance

CategoryDetail
ConditionModerate-to-severe psoriasis
Key MechanismsRisankizumab targets the p19 subunit of interleukin-23, modulating immune response.
Target PopulationAdults aged ≥ 18 years with moderate-to-severe psoriasis.
Care SettingReal-world clinical settings in Israel.

Key Highlights

  • 58% achieved Dermatology Life Quality Index 0/1 after 52 weeks.
  • 81% reported low pruritus (PNRS 0–3).
  • 77% reached static Psoriasis Global Assessment 0/1.
  • Significant reductions in nocturnal scratch duration observed.
  • Improvements noted in sleep, symptoms, work productivity, and activity impairment.

Guideline-Based Recommendations

Diagnosis

  • Clinical diagnosis of moderate-to-severe psoriasis based on symptoms and severity.

Management

  • Risankizumab administered at weeks 0, 4, and every 12 weeks thereafter.

Monitoring & Follow-up

  • Utilization of patient-reported outcomes and digital monitoring for pruritus.

Risks

  • Monitoring for adverse events associated with risankizumab therapy.

Patient & Prescribing Data

Adults with moderate-to-severe psoriasis, naïve to risankizumab.

Integration of digital scratch measures with PROMs may enhance management.

Clinical Best Practices

  • Incorporate PROMs like DLQI and PNRS into routine assessments.
  • Utilize digital monitoring for objective pruritus metrics.
  • Focus on comprehensive management addressing both physical and psychosocial aspects.

References

Original Source(s)

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • by Igor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, Hagit Matz, Yuri Shclar, Sari Murad, Tali Czarnowicki, Eran Shavit, Liuqing Yang, Sandra Goss, Inbal Piller Maor, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Lev Pavlovsky

  • March 31, 2026

Related Content

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Influence of Environmental and Community Factors on Psoriasis: A Comprehensive Review of Pollution, Urban Design, and Socioeconomic Risk Factors